JP6423036B2 - 痛み治療用の医薬配合物 - Google Patents
痛み治療用の医薬配合物 Download PDFInfo
- Publication number
- JP6423036B2 JP6423036B2 JP2017075145A JP2017075145A JP6423036B2 JP 6423036 B2 JP6423036 B2 JP 6423036B2 JP 2017075145 A JP2017075145 A JP 2017075145A JP 2017075145 A JP2017075145 A JP 2017075145A JP 6423036 B2 JP6423036 B2 JP 6423036B2
- Authority
- JP
- Japan
- Prior art keywords
- administration
- pain
- pharmaceutical composition
- component
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
(a)次式(I):
の3−(3−ジメチルアミノ−1−エチル−2−メチルプロピル)−フェノールであって、任意にその純粋な立体異性体の一つ、特にエナンチオマー若しくはジアステレオマーの形態、ラセミ体又はその立体異性体の混合物、特に任意の混合比のエナンチオマー及び/又はジアステレオマーの形態にあるもの、或いは任意の対応するその酸付加塩と、
(b)少なくとも1種のNMDAアンタゴニストと
を含む医薬配合物に関する。
(1R,2R)−3−(3−ジメチルアミノ−1−エチル−2−メチルプロピル)−フェノール、
(1S,2S)−3−(3−ジメチルアミノ−1−エチル−2−メチルプロピル)−フェノール、
(1R,2S)−3−(3−ジメチルアミノ−1−エチル−2−メチルプロピル)−フェノール、
(1S,2R)−3−(3−ジメチルアミノ−1−エチル−2−メチルプロピル)−フェノール、
及びそれらの任意の混合物
から選択される。
(1R,2R)−3−(3−ジメチルアミノ−1−エチル−2−メチルプロピル)−フェノール、及び
(1S,2S)−3−(3−ジメチルアミノ−1−エチル−2−メチルプロピル)−フェノール、並びに
それらの任意の混合物
から選択される。
(a)次式(I’)の化合物(1R,2R)−3−(3−ジメチルアミノ−1−エチル−2−メチルプロピル)−フェノール
ラットでのランダルセリット試験
本発明の医薬組成物の相加効果(相乗効果)に至る成分(a)及び(b)の重量比は、炎症性の痛み又は神経障害性の痛みのモデルにおいて機械的痛覚過敏を評価するのに適合できる機械的痛覚試験である、Arch.Int.Pharmacodyn.,1957,111:409〜419に記載されたランダル及びセリットの試験により決定できる。この文献の各部は引用によりここに含まれ、本明細書の一部をなす。
Claims (13)
- 前記成分(a)及び/又は前記成分(b)の1日当たりの投与量は、成分のそれぞれについて、75±15重量%、75±10重量%、75±5重量%、50±15重量%、50±10重量%、50±5重量%、25±15重量%、25±10重量%及び25±5重量%とすることができる、請求項1記載の医薬組成物。
- 前記式(I’)の化合物の酸付加塩がその塩酸塩付加塩である、請求項1または2に記載の医薬組成物。
- 前記成分(b)の酸付加塩がその塩酸塩付加塩である、請求項1または2に記載の医薬組成物。
- 前記成分(a)及び(b)は、前記配合物が患者への投与に対して相乗効果を発揮する重量比で存在する、請求項1〜4のいずれか1つに記載の医薬組成物。
- 請求項1〜5のいずれか1つに記載の医薬配合物と、任意に1種以上の助剤とを含む医薬組成物。
- 請求項1〜6のいずれか1つに記載の医薬組成物と、任意に1種以上の助剤とを含む製剤。
- 経口投与、静脈内投与、動脈内投与、腹腔内投与、皮内投与、経皮投与、くも膜下投与、筋肉内投与、鼻腔内投与、経粘膜投与、皮下投与又は直腸投与に好適であることを特徴とする、請求項7に記載の製剤。
- 前記成分(a)及び(b)の一方又は両方が放出制御形態で存在する、請求項7又は8に記載の製剤。
- 前記医薬配合物の成分(a)及び成分(b)が同時に又は連続的に投与され、ここで、化合物(a)を化合物(b)の前又は後に投与されてよく、化合物(a)又は(b)が同一の又は異なる投与経路により投与される、請求項7〜9のいずれか1つに記載の製剤。
- 痛みの治療用の、請求項1〜6のいずれか1つに記載の医薬組成物。
- 前記痛みが炎症性痛、神経障害性痛、急性痛、慢性痛、内臓痛、偏頭痛の痛み及び癌の痛みから選択される、請求項11に記載の医薬組成物。
- 前記痛みが炎症性痛である、請求項12に記載の医薬組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10006202.5 | 2010-06-15 | ||
EP10006202 | 2010-06-15 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015151003A Division JP6197007B2 (ja) | 2010-06-15 | 2015-07-30 | 痛み治療用の医薬配合物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017141277A JP2017141277A (ja) | 2017-08-17 |
JP2017141277A5 JP2017141277A5 (ja) | 2017-10-05 |
JP6423036B2 true JP6423036B2 (ja) | 2018-11-14 |
Family
ID=42395008
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013514579A Expired - Fee Related JP6133772B2 (ja) | 2010-06-15 | 2011-06-14 | 痛み治療用の医薬配合物 |
JP2015151003A Expired - Fee Related JP6197007B2 (ja) | 2010-06-15 | 2015-07-30 | 痛み治療用の医薬配合物 |
JP2017075145A Expired - Fee Related JP6423036B2 (ja) | 2010-06-15 | 2017-04-05 | 痛み治療用の医薬配合物 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013514579A Expired - Fee Related JP6133772B2 (ja) | 2010-06-15 | 2011-06-14 | 痛み治療用の医薬配合物 |
JP2015151003A Expired - Fee Related JP6197007B2 (ja) | 2010-06-15 | 2015-07-30 | 痛み治療用の医薬配合物 |
Country Status (29)
Country | Link |
---|---|
US (3) | US8846765B2 (ja) |
EP (2) | EP2992877A1 (ja) |
JP (3) | JP6133772B2 (ja) |
KR (1) | KR101831616B1 (ja) |
CN (1) | CN103108631B (ja) |
AR (1) | AR081931A1 (ja) |
AU (2) | AU2011267474B2 (ja) |
BR (1) | BR112012031836A2 (ja) |
CA (1) | CA2796774C (ja) |
CL (1) | CL2012002551A1 (ja) |
CO (1) | CO6602157A2 (ja) |
CY (1) | CY1117118T1 (ja) |
DK (1) | DK2582366T3 (ja) |
EC (2) | ECSP12012217A (ja) |
ES (1) | ES2560676T3 (ja) |
HK (2) | HK1215787A1 (ja) |
HR (1) | HRP20151327T1 (ja) |
HU (1) | HUE026619T2 (ja) |
IL (1) | IL221926A (ja) |
MX (1) | MX2012014482A (ja) |
NZ (1) | NZ602625A (ja) |
PE (2) | PE20160531A1 (ja) |
PL (1) | PL2582366T3 (ja) |
PT (1) | PT2582366E (ja) |
RS (1) | RS54439B1 (ja) |
RU (2) | RU2589692C2 (ja) |
SI (1) | SI2582366T1 (ja) |
WO (1) | WO2011157391A1 (ja) |
ZA (1) | ZA201208646B (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2992877A1 (en) | 2010-06-15 | 2016-03-09 | Grünenthal GmbH | Pharmaceutical combination for the treatment of pain |
US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
CN104519878A (zh) * | 2012-03-12 | 2015-04-15 | 詹森药业有限公司 | 用于治疗顽固性或难治性抑郁症的艾氯胺酮 |
CA2898619C (en) * | 2013-01-22 | 2021-10-19 | Vistagen Therapeutics, Inc. | Dosage forms and therapeutic uses of l-4-chlorokynurenine |
BR112015022972B1 (pt) | 2013-03-15 | 2023-02-14 | Janssen Pharmaceutica Nv | Composição farmacêutica de cloridrato de s-cetamina e formas de dosagem da mesma |
CN103655523A (zh) * | 2013-12-24 | 2014-03-26 | 南京艾德凯腾生物医药有限责任公司 | 他喷他多组合物 |
RU2721948C2 (ru) * | 2014-05-06 | 2020-05-25 | Нортвестерн Юниверсити | Комбинации соединений, модулирующих nmda-рецептор |
KR20170040800A (ko) | 2014-08-13 | 2017-04-13 | 얀센 파마슈티카 엔.브이. | 우울증 치료 방법 |
EP3725307A1 (en) | 2014-09-15 | 2020-10-21 | Janssen Pharmaceutica NV | Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression |
US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
EP3297620A4 (en) | 2015-06-27 | 2019-01-09 | Shenox Pharmaceuticals, LLC | TRANSDERMAL DELIVERY SYSTEM FOR KETAMINE |
US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
BR112020012473A2 (pt) | 2017-12-22 | 2020-11-24 | Janssen Pharmaceuticals, Inc. | escetamina para o tratamento da depressão |
JP2021521188A (ja) * | 2018-04-12 | 2021-08-26 | アナベックス ライフ サイエンス コーポレイション | 物質のa2−73結晶多形組成物およびそれらの使用方法 |
AU2020231172A1 (en) | 2019-03-05 | 2021-09-23 | Janssen Pharmaceuticals, Inc. | Esketamine for the treatment of depression |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3391142A (en) | 1966-02-09 | 1968-07-02 | Lilly Co Eli | Adamantyl secondary amines |
US4389393A (en) | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
US5472711A (en) | 1992-07-30 | 1995-12-05 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
US5330761A (en) | 1993-01-29 | 1994-07-19 | Edward Mendell Co. Inc. | Bioadhesive tablet for non-systemic use products |
US5455046A (en) | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US5399362A (en) | 1994-04-25 | 1995-03-21 | Edward Mendell Co., Inc. | Once-a-day metoprolol oral dosage form |
DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
US6248789B1 (en) * | 1996-08-29 | 2001-06-19 | Stuart L. Weg | Administration of ketamine to manage pain and to reduce drug dependency |
US6007841A (en) | 1998-03-13 | 1999-12-28 | Algos Pharmaceutical Corporation | Analgesic composition and method for treating pain |
ATE344035T1 (de) * | 1998-07-16 | 2006-11-15 | Memorial Sloan Kettering Inst | Topische zusammensetzung enthaltend ein opioid- analgetikum und einen nmda-antagonisten |
DE10005302A1 (de) * | 2000-02-07 | 2002-01-17 | Gruenenthal Gmbh | Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate |
US20010036943A1 (en) | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
PE20030527A1 (es) * | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
DE10163421A1 (de) | 2001-12-21 | 2003-07-31 | Gruenenthal Gmbh | Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum |
JP2003201254A (ja) * | 2001-12-28 | 2003-07-18 | Hisamitsu Pharmaceut Co Inc | 鎮痛剤活性増強剤の治療上有効な血中濃度を維持するための製剤 |
JP2003210254A (ja) * | 2002-01-18 | 2003-07-29 | Nihon Form Service Co Ltd | 車椅子専用ラック |
EP1545461A4 (en) * | 2002-09-09 | 2011-06-22 | Endo Pharmaceuticals Inc | COMBINED ANALGESIC COMPOSITION WITH IMMEDIATE AND PROLONGED RELEASE |
US7273889B2 (en) * | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
US20090082466A1 (en) * | 2006-01-27 | 2009-03-26 | Najib Babul | Abuse Resistant and Extended Release Formulations and Method of Use Thereof |
US20070254960A1 (en) | 2006-04-28 | 2007-11-01 | Gruenenthal Gmbh | Pharmaceutical combination |
ES2356093T3 (es) | 2006-04-28 | 2011-04-04 | Grünenthal GmbH | Combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metilpropil)fenol y paracetamol. |
PL2012763T3 (pl) | 2006-04-28 | 2011-08-31 | Gruenenthal Gmbh | Kombinacja farmaceutyczna zawierająca 3-(3-dimetyloamino-1-etylo-2-metylo-propylo)-fenol i NSAID |
EP1857463A1 (en) | 2006-05-03 | 2007-11-21 | Ebewe Pharma Ges.m.b.H. Nfg. KG | Peptide having neuroprotective effects |
JP2009539792A (ja) * | 2006-06-08 | 2009-11-19 | シュヴァルツ・ファーマ・アーゲー | 疼痛の医学的状態のための治療組合せ |
SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
DE102007012165A1 (de) * | 2007-03-12 | 2008-09-18 | Grünenthal GmbH | Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes |
EP3170494A3 (en) * | 2007-11-23 | 2017-09-06 | Grünenthal GmbH | Tapentadol compositions |
NZ586792A (en) | 2008-01-25 | 2012-09-28 | Gruenenthal Chemie | Tamper resistant controlled release pharmaceutical tablets form having convex and concave surfaces |
US7872046B2 (en) | 2008-01-25 | 2011-01-18 | Xenoport, Inc. | Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use |
US20100190752A1 (en) | 2008-09-05 | 2010-07-29 | Gruenenthal Gmbh | Pharmaceutical Combination |
TR201904388T4 (tr) * | 2008-09-05 | 2019-05-21 | Gruenenthal Gmbh | Pregabalin veya gabapentin ve 3-(3-dimetilamino-1-etil-2-metil-propil)-fenolün farmasötik kombinasyonu. |
EP2992877A1 (en) * | 2010-06-15 | 2016-03-09 | Grünenthal GmbH | Pharmaceutical combination for the treatment of pain |
MX2013003354A (es) | 2010-09-21 | 2013-06-24 | Purdue Pharma Lp | Analogos de buprenorfina. |
SG10201510564PA (en) | 2010-12-22 | 2016-01-28 | Purdue Pharma Lp | Encased tamper resistant controlled release dosage forms |
EP3025710A1 (en) | 2011-03-04 | 2016-06-01 | Grünenthal GmbH | Parenteral administration of tapentadol |
TWI522101B (zh) | 2012-04-17 | 2016-02-21 | 普渡製藥有限合夥事業 | 處理由類鴉片引起之不利的藥效動力反應之系統和方法 |
-
2011
- 2011-06-14 EP EP15003060.9A patent/EP2992877A1/en not_active Withdrawn
- 2011-06-14 EP EP11730199.4A patent/EP2582366B1/en active Active
- 2011-06-14 MX MX2012014482A patent/MX2012014482A/es active IP Right Grant
- 2011-06-14 PL PL11730199T patent/PL2582366T3/pl unknown
- 2011-06-14 US US13/159,845 patent/US8846765B2/en not_active Expired - Fee Related
- 2011-06-14 NZ NZ602625A patent/NZ602625A/en not_active IP Right Cessation
- 2011-06-14 JP JP2013514579A patent/JP6133772B2/ja not_active Expired - Fee Related
- 2011-06-14 DK DK11730199.4T patent/DK2582366T3/en active
- 2011-06-14 AU AU2011267474A patent/AU2011267474B2/en not_active Ceased
- 2011-06-14 AR ARP110102069A patent/AR081931A1/es not_active Application Discontinuation
- 2011-06-14 KR KR1020127032555A patent/KR101831616B1/ko active IP Right Grant
- 2011-06-14 SI SI201130695T patent/SI2582366T1/sl unknown
- 2011-06-14 PT PT117301994T patent/PT2582366E/pt unknown
- 2011-06-14 BR BR112012031836A patent/BR112012031836A2/pt active Search and Examination
- 2011-06-14 RS RS20150842A patent/RS54439B1/en unknown
- 2011-06-14 RU RU2013101515/15A patent/RU2589692C2/ru active
- 2011-06-14 ES ES11730199.4T patent/ES2560676T3/es active Active
- 2011-06-14 CA CA2796774A patent/CA2796774C/en not_active Expired - Fee Related
- 2011-06-14 HU HUE11730199A patent/HUE026619T2/en unknown
- 2011-06-14 PE PE2016000337A patent/PE20160531A1/es unknown
- 2011-06-14 WO PCT/EP2011/002905 patent/WO2011157391A1/en active Application Filing
- 2011-06-14 CN CN201180029405.2A patent/CN103108631B/zh not_active Expired - Fee Related
- 2011-06-14 PE PE2012002241A patent/PE20130243A1/es active IP Right Grant
-
2012
- 2012-09-13 IL IL221926A patent/IL221926A/en active IP Right Grant
- 2012-09-14 CL CL2012002551A patent/CL2012002551A1/es unknown
- 2012-09-14 CO CO12158816A patent/CO6602157A2/es unknown
- 2012-10-03 EC ECSP12012217 patent/ECSP12012217A/es unknown
- 2012-11-16 ZA ZA2012/08646A patent/ZA201208646B/en unknown
-
2013
- 2013-10-02 HK HK16103593.7A patent/HK1215787A1/zh unknown
- 2013-10-02 HK HK13111233.9A patent/HK1184370A1/zh not_active IP Right Cessation
-
2014
- 2014-06-26 US US14/315,603 patent/US20140309311A1/en not_active Abandoned
-
2015
- 2015-07-30 JP JP2015151003A patent/JP6197007B2/ja not_active Expired - Fee Related
- 2015-12-04 HR HRP20151327TT patent/HRP20151327T1/hr unknown
-
2016
- 2016-01-14 CY CY20161100034T patent/CY1117118T1/el unknown
- 2016-05-17 RU RU2016119041A patent/RU2675261C2/ru active
- 2016-08-25 AU AU2016219643A patent/AU2016219643B2/en not_active Ceased
-
2017
- 2017-04-05 JP JP2017075145A patent/JP6423036B2/ja not_active Expired - Fee Related
- 2017-08-10 US US15/674,407 patent/US10813890B2/en active Active
-
2019
- 2019-07-02 EC ECSENADI201947259A patent/ECSP19047259A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6423036B2 (ja) | 痛み治療用の医薬配合物 | |
JP5496653B2 (ja) | 3−(3−ジメチルアミノ−1−エチル−2−メチル−プロピル)−フェノール、およびパラセタモールを含む医薬の組合せ | |
KR20090007613A (ko) | 3-(3-디메틸아미노-1-에틸-2-메틸-프로필)-페놀 및 nsaid를 포함하는 약제학적 병용제 | |
JP2012501987A (ja) | 6−ジメチルアミノメチル−1−(3−メトキシフェニル)−シクロヘキサン−1,3−ジオールとnsaidを含む医薬の組み合わせ | |
JP2015516447A (ja) | (1r,4r)−6’−フルオロ−N,N−ジメチル−4−フェニル−4’,9’−ジヒドロ−3’H−スピロ[シクロヘキサン−1,1’−ピラノ−[3,4,b]インドール]−4−アミンおよびプロピオン酸誘導体を含む医薬組成物 | |
US20100069501A1 (en) | Pharmaceutical Composition Comprising 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol and Paracetamol | |
JP6116678B2 (ja) | (1r,4r)−6’−フルオロ−N,N−ジメチル−4−フェニル−4’,9’−ジヒドロ−3’H−スピロ[シクロヘキサン−1,1’−ピラノ[3,4,b]インドール]−4−アミンおよびNSARを含む医薬組成物 | |
JP6116676B2 (ja) | (1r,4r)−6’−フルオロ−N,N−ジメチル−4−フェニル−4’,9’−ジヒドロ−3’H−スピロ[シクロヘキサン−1,1’−ピラノ[3,4,b]インドール]−4−アミンおよびパラセタモールまたはプロパセタモールを含む医薬組成物 | |
JP6116677B2 (ja) | (1r,4r)−6’−フルオロ−N,N−ジメチル−4−フェニル−4’,9’−ジヒドロ−3’H−スピロ[シクロヘキサン−1,1’−ピラノ[3,4,b]インドール]−4−アミンおよびオキシカムを含む医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170822 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20180110 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180403 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181003 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181017 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6423036 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |